28-Mar-2026 9:03 PM CST - Yahoo Finance Is CRISPR Therapeutics (CRSP) Attractive After Recent Share Price Pullback? If you are wondering whether CRISPR Therapeutics at around US$45.75 is a bargain or a value trap, the answer depends on how you look at its valuation. The stock has returned 23.7% over the last year,
23-Mar-2026 12:43 PM CST - The Motley Fool CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now? CRISPR recently raised nearly $600 million through a private offering, which weighed down its share price. The company has an approved therapy in Casgevy, but its business remains deeply unprofitable.
17-Mar-2026 9:36 AM CST - Yahoo Finance Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now? Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr Therapeutics Ag (NASDAQ:CRSP) shares are up 16% over the past 12 months. Cathie Wood's ARK increased its stake in the company by 8% in the fourth quarter,
14-Mar-2026 5:08 AM CST - Yahoo Finance Is CRISPR Therapeutics (CRSP) Pricing Reflecting Gene Editing Potential After Recent Share Pullback Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. If you are wondering whether CRISPR Therapeutics at around US$48.75 is a bargain or a concern, the key question is ...
11-Mar-2026 6:30 AM CST - Yahoo Finance CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering CRISPR Therapeutics AG (Nasdaq: CRSP) (the "Company") today announced the pricing of $550 million aggregate principal amount of its convertible senior notes due 2031 (the "notes") in a private offering (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933,
11-Mar-2026 5:00 AM CST - Seeking Alpha Cathie Wood buys the dip in gene-editing firm CRISPR Therapeutics Cathie Wood's ARK Invest added to several beaten-down technology and biotech names while trimming positions elsewhere. The investment manager made a notable purchase in gene-editing company CRISPR Therapeutics (NASDAQ: CRSP),
11-Mar-2026 1:45 AM CST - Yahoo Finance CRISPR Therapeutics Raises US$350m As Undervalued Shares Draw Investor Focus CRISPR Therapeutics (NasdaqGM:CRSP) has announced a $350 million offering of convertible senior notes. The securities are a form of debt that may convert into equity under certain conditions. The company expects to use the proceeds for general corporate purposes,
10-Mar-2026 11:56 AM CST - Benzinga What's going on with CRISPR Therapeutics stock today? CRISPR Therapeutics AG CRSP shares moved lower Tuesday after the biotechnology company outlined plans to raise capital through a new convertible debt offering. The gene-editing firm said it intends to issue $350 million in convertible senior notes due 2031 in a private placement aimed at qualified institutional investors.
28-Mar-2026 9:03 PM CST - Yahoo Finance Is CRISPR Therapeutics (CRSP) Attractive After Recent Share Price Pullback? If you are wondering whether CRISPR Therapeutics at around US$45.75 is a bargain or a value trap, the answer depends on how you look at its valuation. The stock has returned 23.7% over the last year,
23-Mar-2026 12:43 PM CST - The Motley Fool CRISPR Therapeutics Stock: Is It a Bargain Buy Right Now? CRISPR recently raised nearly $600 million through a private offering, which weighed down its share price. The company has an approved therapy in Casgevy, but its business remains deeply unprofitable.
17-Mar-2026 9:36 AM CST - Yahoo Finance Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now? Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr Therapeutics Ag (NASDAQ:CRSP) shares are up 16% over the past 12 months. Cathie Wood's ARK increased its stake in the company by 8% in the fourth quarter,
14-Mar-2026 5:08 AM CST - Yahoo Finance Is CRISPR Therapeutics (CRSP) Pricing Reflecting Gene Editing Potential After Recent Share Pullback Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. If you are wondering whether CRISPR Therapeutics at around US$48.75 is a bargain or a concern, the key question is ...
11-Mar-2026 6:30 AM CST - Yahoo Finance CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering CRISPR Therapeutics AG (Nasdaq: CRSP) (the "Company") today announced the pricing of $550 million aggregate principal amount of its convertible senior notes due 2031 (the "notes") in a private offering (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933,
11-Mar-2026 5:00 AM CST - Seeking Alpha Cathie Wood buys the dip in gene-editing firm CRISPR Therapeutics Cathie Wood's ARK Invest added to several beaten-down technology and biotech names while trimming positions elsewhere. The investment manager made a notable purchase in gene-editing company CRISPR Therapeutics (NASDAQ: CRSP),
11-Mar-2026 1:45 AM CST - Yahoo Finance CRISPR Therapeutics Raises US$350m As Undervalued Shares Draw Investor Focus CRISPR Therapeutics (NasdaqGM:CRSP) has announced a $350 million offering of convertible senior notes. The securities are a form of debt that may convert into equity under certain conditions. The company expects to use the proceeds for general corporate purposes,
10-Mar-2026 11:56 AM CST - Benzinga What's going on with CRISPR Therapeutics stock today? CRISPR Therapeutics AG CRSP shares moved lower Tuesday after the biotechnology company outlined plans to raise capital through a new convertible debt offering. The gene-editing firm said it intends to issue $350 million in convertible senior notes due 2031 in a private placement aimed at qualified institutional investors.
